On one hand, mutations in PHD finger proteins like PHF6 exacerbate leukemia progression, while on the other hand, proteins such as UHRF1 regulate essential pathways in ESCC, affecting tumor growth and therapy resistance. This evidence concerns the gene UHRF1 and neoplasm.